A Scoping Literature Review of Lung HRCT in Connective Tissue Disease: Descriptions and Prediction of Mortality
Main Article Content
Abstract
Background and Objectives: This scoping literature review is intended to describe the characteristic HRCT lung findings related to interstitial lung disease (ILD) which occur in: dermatomyositis/polymyositis (DM/PM), rheumatoid arthritis (RA), Sjogren’s Syndrome (SjS), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). In addition, we examined whether HRCT features in these diseases could predict mortality.
Methods: We reviewed the medical literature from PubMed, EMBASE and Cochran reviews from 1993 to 2021, in DM/PM, RA, SJS, SLE and SSc. The articles were extracted according to defined inclusion/exclusion criteria using standardized forms with double extraction of 20% of the articles Analysis included descriptive statistics plus tabulations for comparisons of frequency, prevalence, and prediction of mortality
Results: Of 478 publications, 110 studies were included. HRCT features consistent with ILD reported with variable prevalence (often depending on study design) in RA (15-43%), SjS (~50%), DM/PM (~60%), SSc (~53%) and SLE (53%) patients. Usual interstitial pneumonia (UIP) frequently predicted mortality as did, less commonly, honeycombing and increasing fibrosis. Other non-HRCT factors such as decreased FVC, DLCO, increased age, smoking and male gender were predictors of mortality in RA and SSc. Additionally, predictors of mortality were: UIP in RA; increased skin involvement in SSC, diffuse alveolar hemorrhage in SLE (although rare) and MDA5 in DM, when available.
Conclusion: ILD and increased fibrosis, by HRCT, is relatively common in these connective tissue diseases and plays a significant role in mortality. Specific occurrences such as UIP (RA), increased skin involvement (SSC), diffuse alveolar hemorrhage (SLE) and MDA 5 (DM) also affected mortality.
Keywords:
HRCT, Lung, RA, DM/PM, Sjogren's e, SLE, SSc, description, prognosis, scoping review
Article Details
How to Cite
THASIA WOODWORTH, Olga Morgan et al.
A Scoping Literature Review of Lung HRCT in Connective Tissue Disease: Descriptions and Prediction of Mortality.
Medical Research Archives, [S.l.], v. 13, n. 7, aug. 2025.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/6602>. Date accessed: 06 dec. 2025.
doi: https://doi.org/10.18103/mra.v13i7.6602.
Section
Review Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Castelino FV, Varga J. Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management. Arthritis Res Ther. 2010;12(4):213. doi:10.1186/ar3097
2. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. Sep 1 2018;198(5):e44-e68. doi:10.1164/rccm.201807-1255ST
3. Hallowell RW, Ascherman DP, Danoff SK. Pulmonary manifestations of polymyositis/dermatomyositis. Semin Respir Crit Care Med. Apr 2014;35(2):239-48. doi:10.1055/s-0034-1371528
4. Fathi M, Vikgren J, Boijsen M, et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum. May 15 2008;59(5):677-85. doi:10.1002/art.23571
5. Kowal-Bielecka O, Landewe R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. May 2009;68(5):620-8. doi:10.1136/ard.2008.096677
6. Matcham F, Scott IC, Rayner L, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum. Oct 2014;44(2):123-30. doi:10.1016/j.semarthrit.2014.05.001
7. Ohno Y, Koyama H, Yoshikawa T, Seki S. State-of-the-Art Imaging of the Lung for Connective Tissue Disease (CTD). Curr Rheumatol Rep. Dec 2015;17(12):69. doi:10.1007/s11926-015-0546-8
8. Winklehner A, Berger N, Maurer B, Distler O, Alkadhi H, Frauenfelder T. Screening for interstitial lung disease in systemic sclerosis: the diagnostic accuracy of HRCT image series with high increment and reduced number of slices. Ann Rheum Dis. Apr 2012;71(4):549-52. doi:10.1136/annrheumdis-2011-200564
9. Prior JA, Jordan KP, Kadam UT. Variations in patient-reported physical health between cardiac and musculoskeletal diseases: systematic review and meta-analysis of population-based studies. Health Qual Life Outcomes. May 30 2015;13:71. doi:10.1186/s12955-015-0265-x
10. Gobi K, Arunachalam VK, Varatharajaperumal RK, Cherian M, Periaswamy G, Rajesh S. The role of ultra-low-dose computed tomography in the detection of pulmonary pathologies: a prospective observational study. Pol J Radiol. 2022;87:e597-e605. doi:10.5114/pjr.2022.121433
11. Nguyen-Kim TDL, Maurer B, Suliman YA, Morsbach F, Distler O, Frauenfelder T. The impact of slice-reduced computed tomography on histogram-based densitometry assessment of lung fibrosis in patients with systemic sclerosis. J Thorac Dis. Apr 2018;10(4):2142-2152. doi:10.21037/jtd.2018.04.39
12. Bastos AL, Correa RA, Ferreira GA. Tomography patterns of lung disease in systemic sclerosis. Radiol Bras. Sep-Oct 2016;49(5):316-321. doi:10.1590/0100-3984.2015.0116
13. Milisenda JC, Selva-O'Callaghan A, Grau JM. The diagnosis and classification of polymyositis. J Autoimmun. Feb-Mar 2014;48-49:118-21. doi:10.1016/j.jaut.2014.01.025
14. Sasaki H, Kohsaka H. Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol. Nov 2018;28(6):913-921. doi:10.1080/14397595.2018.1467257
15. Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle Nerve. May 2015;51(5):638-56. doi:10.1002/mus.24566
16. Li H, Xiong Z, Liu J, Li Y, Zhou B. [Manifestations of the connective tissue associated interstitial lung disease under high resolution computed tomography]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. Aug 28 2017;42(8):934-939. doi:10.11817/j.issn.1672-7347.2017.08.010
17. Materna O, Koubsky K, Padr R, Janousek J. Major left ventricular thrombi in an adolescent with COVID-19-associated inflammatory syndrome. Eur Heart J. Aug 31 2021;42(33):3207. doi:10.1093/eurheartj/ehab165
18. Yamanaka Y, Baba T, Hagiwara E, et al. Radiological images of interstitial pneumonia in mixed connective tissue disease compared with scleroderma and polymyositis/dermatomyositis. Eur J Radiol. Oct 2018;107:26-32. doi:10.1016/j.ejrad.2018.08.005
19. Young A, Vummidi D, Visovatti S, et al. Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis. Arthritis Rheumatol. Aug 2019;71(8):1339-1349. doi:10.1002/art.40862
20. Moore OA, Proudman SM, Goh N, et al. Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease. Clin Exp Rheumatol. Jul-Aug 2015;33(4 Suppl 91):S111-6.
21. Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum. Nov 2011;63(11):3439-47. doi:10.1002/art.30513
22. Zamora AC, Hoskote SS, Abascal-Bolado B, et al. Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome. Respir Med. Sep 2016;118:39-45. doi:10.1016/j.rmed.2016.07.009
23. Tanizawa K, Handa T, Nakashima R, et al. The prognostic value of HRCT in myositis-associated interstitial lung disease. Respir Med. May 2013;107(5):745-52. doi:10.1016/j.rmed.2013.01.014
24. Zhang PL, Yang HX, Zhang LN, et al. [Value of serum YKL-40 in the diagnosis of anti-MDA5-positive patients with dermatomyositis complicated with severe pulmonary injury]. Beijing Da Xue Xue Bao Yi Xue Ban. Dec 18 2021;53(6):1055-1060. doi:10.19723/j.issn.1671-167X.2021.06.008
25. Vojinovic T, Cavazzana I, Ceruti P, et al. Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory Myositis. Clin Rev Allergy Immunol. Feb 2021;60(1):87-94. doi:10.1007/s12016-020-08814-5
26. Ariani A, Silva M, Seletti V, et al. Quantitative chest computed tomography is associated with two prediction models of mortality in interstitial lung disease related to systemic sclerosis. Rheumatology (Oxford). Jun 1 2017;56(6):922-927. doi:10.1093/rheumatology/kew480
27. Kotani T, Takeuchi T, Yoshimatsu Y, et al. Initial limited three-level thin-section computed tomography scorings predict the prognosis of acute/subacute interstitial pneumonia in patients with dermatomyositis. Mod Rheumatol. Sep 2016;26(5):738-43. doi:10.3109/14397595.2015.1134392
28. Wolfe F, Michaud K, Pincus T, Furst D, Keystone E. The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes. Arthritis Rheum. Dec 2005;52(12):3873-9. doi:10.1002/art.21494
29. Reith PE, Freeman JB, Granner DK. Sputum cytology: a valuable addition to the investigation of hypercalcemia. Am Surg. Aug 1977;43(8):538-9.
30. Faraguna MC, Musto F, Crescitelli V, et al. Mucopolysaccharidosis-Plus Syndrome, a Rapidly Progressive Disease: Favorable Impact of a Very Prolonged Steroid Treatment on the Clinical Course in a Child. Genes (Basel). Feb 28 2022;13(3)doi:10.3390/genes13030442
31. Freitas S, Westram AM, Schwander T, et al. Parthenogenesis in Darevskia lizards: A rare outcome of common hybridization, not a common outcome of rare hybridization. Evolution. May 2022;76(5):899-914. doi:10.1111/evo.14462
32. Sibl O, Siblova O, Vesely J. [Endocrine orbital diseases]. Cesk Otolaryngol. May 1989;38(3):129-36. K problemu endokrinni orbitopatie.
33. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. Jan 13 2001;357(9250):96-100. doi:10.1016/S0140-6736(00)03540-6
34. Prideaux N, van den Berg M, Drummond C, Barr C. Augmented Performance Feedback during Robotic Gait Therapy Results in Moderate Intensity Cardiovascular Exercise in Subacute Stroke. J Stroke Cerebrovasc Dis. Jun 2020;29(6):104758. doi:10.1016/j.jstrokecerebrovasdis.2020.104758
35. Kerr SM, Stark GR, Kerr IM. Excess antisense RNA from infectious recombinant SV40 fails to inhibit expression of a transfected, interferon-inducible gene. Eur J Biochem. Jul 15 1988;175(1):65-73. doi:10.1111/j.1432-1033.1988.tb14167.x
36. Legras A, Tallet A, Didelot A, et al. Clinical and molecular characteristics of unicentric mediastinal Castleman disease. J Thorac Dis. Apr 2018;10(4):2079-2088. doi:10.21037/jtd.2018.03.159
37. Khanna D, Distler O, Cottin V, et al. Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography. J Scleroderma Relat Disord. Oct 2022;7(3):168-178. doi:10.1177/23971983211064463
38. Uddin S, Munir MZ, Gull S, et al. Transcriptome Profiling Reveals Role of MicroRNAs and Their Targeted Genes during Adventitious Root Formation in Dark-Pretreated Micro-Shoot Cuttings of Tetraploid Robinia pseudoacacia L. Genes (Basel). Feb 27 2022;13(3)doi:10.3390/genes13030441
39. Schiopu E, Phillips K, MacDonald PM, Crofford LJ, Somers EC. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Res Ther. Jan 27 2012;14(1):R22. doi:10.1186/ar3704
40. Winstone TA, Assayag D, Wilcox PG, et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest. Aug 2014;146(2):422-436. doi:10.1378/chest.13-2626
41. Yin Y, Liang D, Zhao L, et al. Anti-cyclic citrullinated Peptide antibody is associated with interstitial lung disease in patients with rheumatoid arthritis. PLoS One. 2014;9(4):e92449. doi:10.1371/journal.pone.0092449
42. Chen J, Shi Y, Wang X, Huang H, Ascherman D. Asymptomatic preclinical rheumatoid arthritis-associated interstitial lung disease. Clin Dev Immunol. 2013;2013:406927. doi:10.1155/2013/406927
43. Wang JX, Du CG. A retrospective study of clinical characteristics of interstitial lung disease associated with rheumatoid arthritis in Chinese patients. Med Sci Monit. Mar 7 2015;21:708-15. doi:10.12659/MSM.890880
44. Zou YQ, Li YS, Ding XN, Ying ZH. The clinical significance of HRCT in evaluation of patients with rheumatoid arthritis-associated interstitial lung disease: a report from China. Rheumatol Int. Mar 2012;32(3):669-73. doi:10.1007/s00296-010-1665-1
45. Zhang Y, Li H, Wu N, Dong X, Zheng Y. Retrospective study of the clinical characteristics and risk factors of rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol. Apr 2017;36(4):817-823. doi:10.1007/s10067-017-3561-5
46. Li L, Liu R, Zhang Y, et al. A retrospective study on the predictive implications of clinical characteristics and therapeutic management in patients with rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol. May 2020;39(5):1457-1470. doi:10.1007/s10067-019-04846-1
47. Salaffi F, Carotti M, Di Carlo M, Tardella M, Giovagnoni A. High-resolution computed tomography of the lung in patients with rheumatoid arthritis: Prevalence of interstitial lung disease involvement and determinants of abnormalities. Medicine (Baltimore). Sep 2019;98(38):e17088. doi:10.1097/MD.0000000000017088
48. Gautam M, Masood MJ, Arooj S, Mahmud ME, Mukhtar MU. Rheumatoid Arthritis Related Interstitial Lung Disease: Patterns of High-resolution Computed Tomography. Cureus. Feb 4 2020;12(2):e6875. doi:10.7759/cureus.6875
49. Li L, Gao S, Fu Q, et al. A preliminary study of lung abnormalities on HRCT in patients of rheumatoid arthritis-associated interstitial lung disease with progressive fibrosis. Clin Rheumatol. Nov 2019;38(11):3169-3178. doi:10.1007/s10067-019-04673-4
50. Avouac J, Cauvet A, Steelandt A, et al. Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease. PLoS One. 2020;15(5):e0232978. doi:10.1371/journal.pone.0232978
51. Zrour SH, Touzi M, Bejia I, et al. Correlations between high-resolution computed tomography of the chest and clinical function in patients with rheumatoid arthritis. Prospective study in 75 patients. Joint Bone Spine. Jan 2005;72(1):41-7. doi:10.1016/j.jbspin.2004.02.001
52. Wilsher M, Voight L, Milne D, et al. Prevalence of airway and parenchymal abnormalities in newly diagnosed rheumatoid arthritis. Respir Med. Oct 2012;106(10):1441-6. doi:10.1016/j.rmed.2012.06.020
53. Hanaka T, Kido T, Ishimoto H, et al. Radiological patterns of pulmonary involvement may predict treatment response in rheumatoid arthritis: A retrospective study. Respir Investig. Mar 2019;57(2):172-182. doi:10.1016/j.resinv.2018.12.006
54. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. Jun 2010;35(6):1322-8. doi:10.1183/09031936.00092309
55. Ekici M, Baytar Y, Kardas RC, et al. Predictors of mortality in rheumatoid arthritis-associated lung disease: A retrospective study on ten years. Joint Bone Spine. May 2021;88(3):105133. doi:10.1016/j.jbspin.2021.105133
56. Kim HC, Lee JS, Lee EY, et al. Risk prediction model in rheumatoid arthritis-associated interstitial lung disease. Respirology. Dec 2020;25(12):1257-1264. doi:10.1111/resp.13848
57. Ito Y, Arita M, Kumagai S, et al. Radiological fibrosis score is strongly associated with worse survival in rheumatoid arthritis-related interstitial lung disease. Mod Rheumatol. Jan 2019;29(1):98-104. doi:10.1080/14397595.2018.1442170
58. Yunt ZX, Chung JH, Hobbs S, et al. High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: Relationship to survival. Respir Med. May 2017;126:100-104. doi:10.1016/j.rmed.2017.03.027
59. Nurmi HM, Kettunen HP, Suoranta SK, et al. Several high-resolution computed tomography findings associate with survival and clinical features in rheumatoid arthritis-associated interstitial lung disease. Respir Med. Jan 2018;134:24-30. doi:10.1016/j.rmed.2017.11.013
60. Yamakawa H, Sato S, Tsumiyama E, et al. Predictive factors of mortality in rheumatoid arthritis-associated interstitial lung disease analysed by modified HRCT classification of idiopathic pulmonary fibrosis according to the 2018 ATS/ERS/JRS/ALAT criteria. J Thorac Dis. Dec 2019;11(12):5247-5257. doi:10.21037/jtd.2019.11.73
61. Biederer J, Schnabel A, Muhle C, Gross WL, Heller M, Reuter M. Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associated with rheumatoid arthritis. Eur Radiol. Feb 2004;14(2):272-80. doi:10.1007/s00330-003-2026-1
62. Yang JA, Lee JS, Park JK, Lee EB, Song YW, Lee EY. Clinical characteristics associated with occurrence and poor prognosis of interstitial lung disease in rheumatoid arthritis. Korean J Intern Med. Mar 2019;34(2):434-441. doi:10.3904/kjim.2016.349
63. Fu Q, Wang L, Li L, Li Y, Liu R, Zheng Y. Risk factors for progression and prognosis of rheumatoid arthritis-associated interstitial lung disease: single center study with a large sample of Chinese population. Clin Rheumatol. Apr 2019;38(4):1109-1116. doi:10.1007/s10067-018-4382-x
64. Solomon JJ, Chung JH, Cosgrove GP, et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. Feb 2016;47(2):588-96. doi:10.1183/13993003.00357-2015
65. Kelly CA, Saravanan V, Nisar M, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study. Rheumatology (Oxford). Sep 2014;53(9):1676-82. doi:10.1093/rheumatology/keu165
66. Suleman Y, Clark KEN, Cole AR, Ong VH, Denton CP. Real-world experience of tocilizumab in systemic sclerosis: potential benefit on lung function for anti-topoisomerase-positive patients. Rheumatology (Oxford). Aug 2 2021;60(8):3945-3946. doi:10.1093/rheumatology/keab273
67. Kotani T, Takeuchi T, Makino S, et al. Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clin Rheumatol. Aug 2011;30(8):1021-8. doi:10.1007/s10067-011-1713-6
68. Go DJ, Lee EY, Lee EB, Song YW, Konig MF, Park JK. Elevated Erythrocyte Sedimentation Rate Is Predictive of Interstitial Lung Disease and Mortality in Dermatomyositis: a Korean Retrospective Cohort Study. J Korean Med Sci. Mar 2016;31(3):389-96. doi:10.3346/jkms.2016.31.3.389
69. Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med. Oct 1 2001;164(7):1182-5. doi:10.1164/ajrccm.164.7.2103110
70. Ikeda S, Arita M, Misaki K, et al. Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study. Springerplus. 2015;4:240. doi:10.1186/s40064-015-1013-8
71. Begleiter A, Robotham E, Lacey G, Leith MK. Increased sensitivity of quinone resistant cells to mitomycin C. Cancer Lett. Jun 1989;45(3):173-6. doi:10.1016/0304-3835(89)90073-6
72. Kim YJ, Choe J, Kim HJ, Song JW. Long-term clinical course and outcome in patients with primary Sjogren syndrome-associated interstitial lung disease. Sci Rep. Jun 18 2021;11(1):12827. doi:10.1038/s41598-021-92024-2
73. Fenlon HM, Doran M, Sant SM, Breatnach E. High-resolution chest CT in systemic lupus erythematosus. AJR Am J Roentgenol. Feb 1996;166(2):301-7. doi:10.2214/ajr.166.2.8553934
74. Alamoudi OS, Attar SM. Pulmonary manifestations in systemic lupus erythematosus: association with disease activity. Respirology. Apr 2015;20(3):474-80. doi:10.1111/resp.12473
75. Enomoto N, Egashira R, Tabata K, et al. Analysis of systemic lupus erythematosus-related interstitial pneumonia: a retrospective multicentre study. Sci Rep. May 14 2019;9(1):7355. doi:10.1038/s41598-019-43782-7
76. Murphy SS. First impressions on a spinal cord injury unit. SCI Nurs. Spring 1988;5(2):21.
77. Ooi GC, Ngan H, Peh WC, Mok MY, Ip M. Systemic lupus erythematosus patients with respiratory symptoms: the value of HRCT. Clin Radiol. Oct 1997;52(10):775-81. doi:10.1016/s0009-9260(97)80159-6
78. Hariri LP, Unizony S, Stone J, et al. Acute fibrinous and organizing pneumonia in systemic lupus erythematosus: a case report and review of the literature. Pathol Int. Nov 2010;60(11):755-9. doi:10.1111/j.1440-1827.2010.02586.x
79. Quadrelli SA, Alvarez C, Arce SC, et al. Pulmonary involvement of systemic lupus erythematosus: analysis of 90 necropsies. Lupus. Oct 2009;18(12):1053-60. doi:10.1177/0961203309106601
80. Spira D, Wirths S, Skowronski F, et al. Diffuse alveolar hemorrhage in patients with hematological malignancies: HRCT patterns of pulmonary involvement and disease course. Clin Imaging. Jul-Aug 2013;37(4):680-6. doi:10.1016/j.clinimag.2012.11.005
81. Andrade C, Mendonca T, Farinha F, et al. Alveolar hemorrhage in systemic lupus erythematosus: a cohort review. Lupus. Jan 2016;25(1):75-80. doi:10.1177/0961203315605365
82. Kwok SK, Moon SJ, Ju JH, et al. Diffuse alveolar hemorrhage in systemic lupus erythematosus: risk factors and clinical outcome: results from affiliated hospitals of Catholic University of Korea. Lupus. Jan 2011;20(1):102-7. doi:10.1177/0961203310381511
83. MacDonald SL, Rubens MB, Hansell DM, et al. Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT. Radiology. Dec 2001;221(3):600-5. doi:10.1148/radiol.2213010158
84. Ioachimescu OC, Stoller JK. Diffuse alveolar hemorrhage: diagnosing it and finding the cause. Cleve Clin J Med. Apr 2008;75(4):258, 260, 264-5 passim. doi:10.3949/ccjm.75.4.258
85. Flaherty KR, Travis WD, Colby TV, et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med. Nov 1 2001;164(9):1722-7. doi:10.1164/ajrccm.164.9.2103074
86. Fang X, Luo B, Yi X, et al. Usual interstitial pneumonia coexisted with nonspecific interstitial pneumonia, What's the diagnosis? Diagn Pathol. Dec 3 2012;7:167. doi:10.1186/1746-1596-7-167
87. Perez HD, Kramer N. Pulmonary hypertension in systemic lupus erythematosus: report of four cases and review of the literature. Semin Arthritis Rheum. Aug 1981;11(1):177-81. doi:10.1016/0049-0172(81)90098-6
88. Kim HG, Tashkin DP, Clements PJ, et al. A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients. Clin Exp Rheumatol. Sep-Oct 2010;28(5 Suppl 62):S26-35.
89. Sant SM, Doran M, Fenelon HM, Breatnach ES. Pleuropulmonary abnormalities in patients with systemic lupus erythematosus: assessment with high resolution computed tomography, chest radiography and pulmonary function tests. Clin Exp Rheumatol. Sep-Oct 1997;15(5):507-13.
90. Furuta GT, Atkins D, Capocelli KE, de Zoeten EF, Fleischer D, Menard-Katcher C. Antitumor necrosis factor, infliximab, and adalimumab: use with caution in eosinophilic bowel disease. J Pediatr Gastroenterol Nutr. Oct 2013;57(4):e25. doi:10.1097/MPG.0b013e3182a1e13b
91. Hoffmann-Vold AM, Fretheim H, Halse AK, et al. Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort. Am J Respir Crit Care Med. Nov 15 2019;200(10):1258-1266. doi:10.1164/rccm.201903-0486OC
92. Le Gouellec N, Duhamel A, Perez T, et al. Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease. PLoS One. 2017;12(8):e0181692. doi:10.1371/journal.pone.0181692
93. Hax V, Bredemeier M, Didonet Moro AL, et al. Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis. Semin Arthritis Rheum. Oct 2017;47(2):228-234. doi:10.1016/j.semarthrit.2017.03.019
94. de Oliveira Martins LV, Oliveira SM, Silvatti J, de Amorim FG, Agapito Tito CV, Kayser C. Mortality in Systemic Sclerosis-Associated Interstitial Lung Disease in Brazil: A Real-Life, Long-Term Follow-up Observational Study. J Clin Rheumatol. Mar 1 2022;28(2):e532-e538. doi:10.1097/RHU.0000000000001792
95. Rivas-Vargas D, Snih SA, Rodriguez MA. Characterization of Venezuelan Patients With Systemic Sclerosis: A Study in a Tertiary Hospital in Caracas. Reumatol Clin (Engl Ed). Oct 7 2020;doi:10.1016/j.reuma.2020.06.006
96. Els Vandecasteele KM, Kristof Thevissen, Michel De Pauww, Ellen Deschepper, sasaki Decuman, Yves Piette, FILIP De Keyser, Guy Brusselle, Vanessa Smith. Prevalence and incidence of pulmonary arterial hypertension: 10-year follow-up of an unselected systemic sclerosis cohort. original article. Journal of Scleroderma and Related Disorders. November 28, 2017 2017;2(3):196-202.
97. Mulkoju R, Saka VK, Rajaram M, et al. Pulmonary Manifestations in Systemic Sclerosis: Hospital-Based Descriptive Study. Cureus. Jun 16 2020;12(6):e8649. doi:10.7759/cureus.8649
98. Noviani M, Saffari SE, Tan JL, et al. Mortality and hospitalization outcomes of interstitial lung disease and pulmonary hypertension in the Singapore systemic sclerosis cohort. Semin Arthritis Rheum. Jun 2020;50(3):473-479. doi:10.1016/j.semarthrit.2019.11.005
99. Sanchez-Cano D, Ortego-Centeno N, Callejas JL, et al. Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group. Rheumatol Int. Mar 2018;38(3):363-374. doi:10.1007/s00296-017-3916-x
100. Fujita J, Yoshinouchi T, Ohtsuki Y, et al. Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis. Ann Rheum Dis. Mar 2001;60(3):281-3. doi:10.1136/ard.60.3.281
101. Okamoto M, Fujimoto K, Sadohara J, et al. A retrospective cohort study of outcome in systemic sclerosis-associated interstitial lung disease. Respir Investig. Nov 2016;54(6):445-453. doi:10.1016/j.resinv.2016.05.004
102. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. Jun 1 2008;177(11):1248-54. doi:10.1164/rccm.200706-877OC
103. Bocchino M, Bruzzese D, D'Alto M, et al. Performance of a new quantitative computed tomography index for interstitial lung disease assessment in systemic sclerosis. Sci Rep. Jul 1 2019;9(1):9468. doi:10.1038/s41598-019-45990-7
104. Vanaken L, Landini N, Lenaerts J, et al. Progressive lung fibrosis and mortality can occur in early systemic sclerosis patients without pulmonary abnormalities at baseline assessment. Clin Rheumatol. Nov 2020;39(11):3393-3400. doi:10.1007/s10067-020-05105-4
105. Zuhur F, Zuhur SS, Zuhur C, Musellim B, Ongen G. Survival in progressive systemic sclerosis with pulmonary involvement: a single-center experience in Istanbul, Turkey. Rheumatol Int. Jun 2012;32(6):1655-61. doi:10.1007/s00296-011-1842-x
106. Takei R, Arita M, Kumagai S, et al. Radiographic fibrosis score predicts survival in systemic sclerosis-associated interstitial lung disease. Respirology. Apr 2018;23(4):385-391. doi:10.1111/resp.13175
107. Moore OA, Goh N, Corte T, et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford). Jan 2013;52(1):155-60. doi:10.1093/rheumatology/kes289
108. Forestier A, Le Gouellec N, Behal H, et al. Evolution of high-resolution CT-scan in systemic sclerosis-associated interstitial lung disease: Description and prognosis factors. Semin Arthritis Rheum. Dec 2020;50(6):1406-1413. doi:10.1016/j.semarthrit.2020.02.015
109. Ariani A. Quantitative Computed Tomography in Systemic Sclerosis-Interstitial Lung Disease: Are We Ready to Go beyond Standard Assessment? Ann Am Thorac Soc. Jan 2021;18(1):183-184. doi:10.1513/AnnalsATS.202008-967LE
110. Goldin JG, Lynch DA, Strollo DC, et al. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest. Aug 2008;134(2):358-367. doi:10.1378/chest.07-2444
111. Kimura N, Gu E, Fujihata T, Kato H. [Ratio of 3 major nutrients compounded in complete intravenous hyperalimentation]. Nihon Rinsho. 1979;37(8):2954-9.
112. Chen M, Liu X, Xu Y, et al. Clinicopathological characteristics of lung cancer in patients with systemic sclerosis. Clin Respir J. Dec 2020;14(12):1131-1136. doi:10.1111/crj.13249
113. Murgia N, Gambelunghe A. Occupational COPD-The most under-recognized occupational lung disease? Respirology. Jun 2022;27(6):399-410. doi:10.1111/resp.14272
114. Duncan F. Moore EK, Rami Eltaraboulsi, Virginia D. Steen. Increased Morbidity and Mortality of Scleroderma in African Americans Compared to Non–African Americans. 1154. Arthritis Care & Research. 2019;71(9):1154-1163. doi:doi 10.1002/acr.23861
115. Goh NS, Hoyles RK, Denton CP, et al. Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis. Arthritis Rheumatol. Aug 2017;69(8):1670-1678. doi:10.1002/art.40130
116. Wang Y, Gargani L, Barskova T, Furst DE, Cerinic MM. Usefulness of lung ultrasound B-lines in connective tissue disease-associated interstitial lung disease: a literature review. Arthritis Res Ther. Sep 18 2017;19(1):206. doi:10.1186/s13075-017-1409-7
117. Kim EA, Lee KS, Johkoh T, et al. Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings. Radiographics. Oct 2002;22 Spec No:S151-65. doi:10.1148/radiographics.22.suppl_1.g02oc04s151
118. Xu L, Yang R, Cao Y, Wang M, Yang X. Risk factors of diffuse alveolar hemorrhage in Chinese patients with systemic lupus erythematosus. Sci Rep. Dec 16 2023;13(1):22381. doi:10.1038/s41598-023-49978-2
2. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. Sep 1 2018;198(5):e44-e68. doi:10.1164/rccm.201807-1255ST
3. Hallowell RW, Ascherman DP, Danoff SK. Pulmonary manifestations of polymyositis/dermatomyositis. Semin Respir Crit Care Med. Apr 2014;35(2):239-48. doi:10.1055/s-0034-1371528
4. Fathi M, Vikgren J, Boijsen M, et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum. May 15 2008;59(5):677-85. doi:10.1002/art.23571
5. Kowal-Bielecka O, Landewe R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. May 2009;68(5):620-8. doi:10.1136/ard.2008.096677
6. Matcham F, Scott IC, Rayner L, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum. Oct 2014;44(2):123-30. doi:10.1016/j.semarthrit.2014.05.001
7. Ohno Y, Koyama H, Yoshikawa T, Seki S. State-of-the-Art Imaging of the Lung for Connective Tissue Disease (CTD). Curr Rheumatol Rep. Dec 2015;17(12):69. doi:10.1007/s11926-015-0546-8
8. Winklehner A, Berger N, Maurer B, Distler O, Alkadhi H, Frauenfelder T. Screening for interstitial lung disease in systemic sclerosis: the diagnostic accuracy of HRCT image series with high increment and reduced number of slices. Ann Rheum Dis. Apr 2012;71(4):549-52. doi:10.1136/annrheumdis-2011-200564
9. Prior JA, Jordan KP, Kadam UT. Variations in patient-reported physical health between cardiac and musculoskeletal diseases: systematic review and meta-analysis of population-based studies. Health Qual Life Outcomes. May 30 2015;13:71. doi:10.1186/s12955-015-0265-x
10. Gobi K, Arunachalam VK, Varatharajaperumal RK, Cherian M, Periaswamy G, Rajesh S. The role of ultra-low-dose computed tomography in the detection of pulmonary pathologies: a prospective observational study. Pol J Radiol. 2022;87:e597-e605. doi:10.5114/pjr.2022.121433
11. Nguyen-Kim TDL, Maurer B, Suliman YA, Morsbach F, Distler O, Frauenfelder T. The impact of slice-reduced computed tomography on histogram-based densitometry assessment of lung fibrosis in patients with systemic sclerosis. J Thorac Dis. Apr 2018;10(4):2142-2152. doi:10.21037/jtd.2018.04.39
12. Bastos AL, Correa RA, Ferreira GA. Tomography patterns of lung disease in systemic sclerosis. Radiol Bras. Sep-Oct 2016;49(5):316-321. doi:10.1590/0100-3984.2015.0116
13. Milisenda JC, Selva-O'Callaghan A, Grau JM. The diagnosis and classification of polymyositis. J Autoimmun. Feb-Mar 2014;48-49:118-21. doi:10.1016/j.jaut.2014.01.025
14. Sasaki H, Kohsaka H. Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol. Nov 2018;28(6):913-921. doi:10.1080/14397595.2018.1467257
15. Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle Nerve. May 2015;51(5):638-56. doi:10.1002/mus.24566
16. Li H, Xiong Z, Liu J, Li Y, Zhou B. [Manifestations of the connective tissue associated interstitial lung disease under high resolution computed tomography]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. Aug 28 2017;42(8):934-939. doi:10.11817/j.issn.1672-7347.2017.08.010
17. Materna O, Koubsky K, Padr R, Janousek J. Major left ventricular thrombi in an adolescent with COVID-19-associated inflammatory syndrome. Eur Heart J. Aug 31 2021;42(33):3207. doi:10.1093/eurheartj/ehab165
18. Yamanaka Y, Baba T, Hagiwara E, et al. Radiological images of interstitial pneumonia in mixed connective tissue disease compared with scleroderma and polymyositis/dermatomyositis. Eur J Radiol. Oct 2018;107:26-32. doi:10.1016/j.ejrad.2018.08.005
19. Young A, Vummidi D, Visovatti S, et al. Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis. Arthritis Rheumatol. Aug 2019;71(8):1339-1349. doi:10.1002/art.40862
20. Moore OA, Proudman SM, Goh N, et al. Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease. Clin Exp Rheumatol. Jul-Aug 2015;33(4 Suppl 91):S111-6.
21. Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum. Nov 2011;63(11):3439-47. doi:10.1002/art.30513
22. Zamora AC, Hoskote SS, Abascal-Bolado B, et al. Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome. Respir Med. Sep 2016;118:39-45. doi:10.1016/j.rmed.2016.07.009
23. Tanizawa K, Handa T, Nakashima R, et al. The prognostic value of HRCT in myositis-associated interstitial lung disease. Respir Med. May 2013;107(5):745-52. doi:10.1016/j.rmed.2013.01.014
24. Zhang PL, Yang HX, Zhang LN, et al. [Value of serum YKL-40 in the diagnosis of anti-MDA5-positive patients with dermatomyositis complicated with severe pulmonary injury]. Beijing Da Xue Xue Bao Yi Xue Ban. Dec 18 2021;53(6):1055-1060. doi:10.19723/j.issn.1671-167X.2021.06.008
25. Vojinovic T, Cavazzana I, Ceruti P, et al. Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory Myositis. Clin Rev Allergy Immunol. Feb 2021;60(1):87-94. doi:10.1007/s12016-020-08814-5
26. Ariani A, Silva M, Seletti V, et al. Quantitative chest computed tomography is associated with two prediction models of mortality in interstitial lung disease related to systemic sclerosis. Rheumatology (Oxford). Jun 1 2017;56(6):922-927. doi:10.1093/rheumatology/kew480
27. Kotani T, Takeuchi T, Yoshimatsu Y, et al. Initial limited three-level thin-section computed tomography scorings predict the prognosis of acute/subacute interstitial pneumonia in patients with dermatomyositis. Mod Rheumatol. Sep 2016;26(5):738-43. doi:10.3109/14397595.2015.1134392
28. Wolfe F, Michaud K, Pincus T, Furst D, Keystone E. The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes. Arthritis Rheum. Dec 2005;52(12):3873-9. doi:10.1002/art.21494
29. Reith PE, Freeman JB, Granner DK. Sputum cytology: a valuable addition to the investigation of hypercalcemia. Am Surg. Aug 1977;43(8):538-9.
30. Faraguna MC, Musto F, Crescitelli V, et al. Mucopolysaccharidosis-Plus Syndrome, a Rapidly Progressive Disease: Favorable Impact of a Very Prolonged Steroid Treatment on the Clinical Course in a Child. Genes (Basel). Feb 28 2022;13(3)doi:10.3390/genes13030442
31. Freitas S, Westram AM, Schwander T, et al. Parthenogenesis in Darevskia lizards: A rare outcome of common hybridization, not a common outcome of rare hybridization. Evolution. May 2022;76(5):899-914. doi:10.1111/evo.14462
32. Sibl O, Siblova O, Vesely J. [Endocrine orbital diseases]. Cesk Otolaryngol. May 1989;38(3):129-36. K problemu endokrinni orbitopatie.
33. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. Jan 13 2001;357(9250):96-100. doi:10.1016/S0140-6736(00)03540-6
34. Prideaux N, van den Berg M, Drummond C, Barr C. Augmented Performance Feedback during Robotic Gait Therapy Results in Moderate Intensity Cardiovascular Exercise in Subacute Stroke. J Stroke Cerebrovasc Dis. Jun 2020;29(6):104758. doi:10.1016/j.jstrokecerebrovasdis.2020.104758
35. Kerr SM, Stark GR, Kerr IM. Excess antisense RNA from infectious recombinant SV40 fails to inhibit expression of a transfected, interferon-inducible gene. Eur J Biochem. Jul 15 1988;175(1):65-73. doi:10.1111/j.1432-1033.1988.tb14167.x
36. Legras A, Tallet A, Didelot A, et al. Clinical and molecular characteristics of unicentric mediastinal Castleman disease. J Thorac Dis. Apr 2018;10(4):2079-2088. doi:10.21037/jtd.2018.03.159
37. Khanna D, Distler O, Cottin V, et al. Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography. J Scleroderma Relat Disord. Oct 2022;7(3):168-178. doi:10.1177/23971983211064463
38. Uddin S, Munir MZ, Gull S, et al. Transcriptome Profiling Reveals Role of MicroRNAs and Their Targeted Genes during Adventitious Root Formation in Dark-Pretreated Micro-Shoot Cuttings of Tetraploid Robinia pseudoacacia L. Genes (Basel). Feb 27 2022;13(3)doi:10.3390/genes13030441
39. Schiopu E, Phillips K, MacDonald PM, Crofford LJ, Somers EC. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Res Ther. Jan 27 2012;14(1):R22. doi:10.1186/ar3704
40. Winstone TA, Assayag D, Wilcox PG, et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest. Aug 2014;146(2):422-436. doi:10.1378/chest.13-2626
41. Yin Y, Liang D, Zhao L, et al. Anti-cyclic citrullinated Peptide antibody is associated with interstitial lung disease in patients with rheumatoid arthritis. PLoS One. 2014;9(4):e92449. doi:10.1371/journal.pone.0092449
42. Chen J, Shi Y, Wang X, Huang H, Ascherman D. Asymptomatic preclinical rheumatoid arthritis-associated interstitial lung disease. Clin Dev Immunol. 2013;2013:406927. doi:10.1155/2013/406927
43. Wang JX, Du CG. A retrospective study of clinical characteristics of interstitial lung disease associated with rheumatoid arthritis in Chinese patients. Med Sci Monit. Mar 7 2015;21:708-15. doi:10.12659/MSM.890880
44. Zou YQ, Li YS, Ding XN, Ying ZH. The clinical significance of HRCT in evaluation of patients with rheumatoid arthritis-associated interstitial lung disease: a report from China. Rheumatol Int. Mar 2012;32(3):669-73. doi:10.1007/s00296-010-1665-1
45. Zhang Y, Li H, Wu N, Dong X, Zheng Y. Retrospective study of the clinical characteristics and risk factors of rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol. Apr 2017;36(4):817-823. doi:10.1007/s10067-017-3561-5
46. Li L, Liu R, Zhang Y, et al. A retrospective study on the predictive implications of clinical characteristics and therapeutic management in patients with rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol. May 2020;39(5):1457-1470. doi:10.1007/s10067-019-04846-1
47. Salaffi F, Carotti M, Di Carlo M, Tardella M, Giovagnoni A. High-resolution computed tomography of the lung in patients with rheumatoid arthritis: Prevalence of interstitial lung disease involvement and determinants of abnormalities. Medicine (Baltimore). Sep 2019;98(38):e17088. doi:10.1097/MD.0000000000017088
48. Gautam M, Masood MJ, Arooj S, Mahmud ME, Mukhtar MU. Rheumatoid Arthritis Related Interstitial Lung Disease: Patterns of High-resolution Computed Tomography. Cureus. Feb 4 2020;12(2):e6875. doi:10.7759/cureus.6875
49. Li L, Gao S, Fu Q, et al. A preliminary study of lung abnormalities on HRCT in patients of rheumatoid arthritis-associated interstitial lung disease with progressive fibrosis. Clin Rheumatol. Nov 2019;38(11):3169-3178. doi:10.1007/s10067-019-04673-4
50. Avouac J, Cauvet A, Steelandt A, et al. Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease. PLoS One. 2020;15(5):e0232978. doi:10.1371/journal.pone.0232978
51. Zrour SH, Touzi M, Bejia I, et al. Correlations between high-resolution computed tomography of the chest and clinical function in patients with rheumatoid arthritis. Prospective study in 75 patients. Joint Bone Spine. Jan 2005;72(1):41-7. doi:10.1016/j.jbspin.2004.02.001
52. Wilsher M, Voight L, Milne D, et al. Prevalence of airway and parenchymal abnormalities in newly diagnosed rheumatoid arthritis. Respir Med. Oct 2012;106(10):1441-6. doi:10.1016/j.rmed.2012.06.020
53. Hanaka T, Kido T, Ishimoto H, et al. Radiological patterns of pulmonary involvement may predict treatment response in rheumatoid arthritis: A retrospective study. Respir Investig. Mar 2019;57(2):172-182. doi:10.1016/j.resinv.2018.12.006
54. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. Jun 2010;35(6):1322-8. doi:10.1183/09031936.00092309
55. Ekici M, Baytar Y, Kardas RC, et al. Predictors of mortality in rheumatoid arthritis-associated lung disease: A retrospective study on ten years. Joint Bone Spine. May 2021;88(3):105133. doi:10.1016/j.jbspin.2021.105133
56. Kim HC, Lee JS, Lee EY, et al. Risk prediction model in rheumatoid arthritis-associated interstitial lung disease. Respirology. Dec 2020;25(12):1257-1264. doi:10.1111/resp.13848
57. Ito Y, Arita M, Kumagai S, et al. Radiological fibrosis score is strongly associated with worse survival in rheumatoid arthritis-related interstitial lung disease. Mod Rheumatol. Jan 2019;29(1):98-104. doi:10.1080/14397595.2018.1442170
58. Yunt ZX, Chung JH, Hobbs S, et al. High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: Relationship to survival. Respir Med. May 2017;126:100-104. doi:10.1016/j.rmed.2017.03.027
59. Nurmi HM, Kettunen HP, Suoranta SK, et al. Several high-resolution computed tomography findings associate with survival and clinical features in rheumatoid arthritis-associated interstitial lung disease. Respir Med. Jan 2018;134:24-30. doi:10.1016/j.rmed.2017.11.013
60. Yamakawa H, Sato S, Tsumiyama E, et al. Predictive factors of mortality in rheumatoid arthritis-associated interstitial lung disease analysed by modified HRCT classification of idiopathic pulmonary fibrosis according to the 2018 ATS/ERS/JRS/ALAT criteria. J Thorac Dis. Dec 2019;11(12):5247-5257. doi:10.21037/jtd.2019.11.73
61. Biederer J, Schnabel A, Muhle C, Gross WL, Heller M, Reuter M. Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associated with rheumatoid arthritis. Eur Radiol. Feb 2004;14(2):272-80. doi:10.1007/s00330-003-2026-1
62. Yang JA, Lee JS, Park JK, Lee EB, Song YW, Lee EY. Clinical characteristics associated with occurrence and poor prognosis of interstitial lung disease in rheumatoid arthritis. Korean J Intern Med. Mar 2019;34(2):434-441. doi:10.3904/kjim.2016.349
63. Fu Q, Wang L, Li L, Li Y, Liu R, Zheng Y. Risk factors for progression and prognosis of rheumatoid arthritis-associated interstitial lung disease: single center study with a large sample of Chinese population. Clin Rheumatol. Apr 2019;38(4):1109-1116. doi:10.1007/s10067-018-4382-x
64. Solomon JJ, Chung JH, Cosgrove GP, et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. Feb 2016;47(2):588-96. doi:10.1183/13993003.00357-2015
65. Kelly CA, Saravanan V, Nisar M, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study. Rheumatology (Oxford). Sep 2014;53(9):1676-82. doi:10.1093/rheumatology/keu165
66. Suleman Y, Clark KEN, Cole AR, Ong VH, Denton CP. Real-world experience of tocilizumab in systemic sclerosis: potential benefit on lung function for anti-topoisomerase-positive patients. Rheumatology (Oxford). Aug 2 2021;60(8):3945-3946. doi:10.1093/rheumatology/keab273
67. Kotani T, Takeuchi T, Makino S, et al. Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clin Rheumatol. Aug 2011;30(8):1021-8. doi:10.1007/s10067-011-1713-6
68. Go DJ, Lee EY, Lee EB, Song YW, Konig MF, Park JK. Elevated Erythrocyte Sedimentation Rate Is Predictive of Interstitial Lung Disease and Mortality in Dermatomyositis: a Korean Retrospective Cohort Study. J Korean Med Sci. Mar 2016;31(3):389-96. doi:10.3346/jkms.2016.31.3.389
69. Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med. Oct 1 2001;164(7):1182-5. doi:10.1164/ajrccm.164.7.2103110
70. Ikeda S, Arita M, Misaki K, et al. Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study. Springerplus. 2015;4:240. doi:10.1186/s40064-015-1013-8
71. Begleiter A, Robotham E, Lacey G, Leith MK. Increased sensitivity of quinone resistant cells to mitomycin C. Cancer Lett. Jun 1989;45(3):173-6. doi:10.1016/0304-3835(89)90073-6
72. Kim YJ, Choe J, Kim HJ, Song JW. Long-term clinical course and outcome in patients with primary Sjogren syndrome-associated interstitial lung disease. Sci Rep. Jun 18 2021;11(1):12827. doi:10.1038/s41598-021-92024-2
73. Fenlon HM, Doran M, Sant SM, Breatnach E. High-resolution chest CT in systemic lupus erythematosus. AJR Am J Roentgenol. Feb 1996;166(2):301-7. doi:10.2214/ajr.166.2.8553934
74. Alamoudi OS, Attar SM. Pulmonary manifestations in systemic lupus erythematosus: association with disease activity. Respirology. Apr 2015;20(3):474-80. doi:10.1111/resp.12473
75. Enomoto N, Egashira R, Tabata K, et al. Analysis of systemic lupus erythematosus-related interstitial pneumonia: a retrospective multicentre study. Sci Rep. May 14 2019;9(1):7355. doi:10.1038/s41598-019-43782-7
76. Murphy SS. First impressions on a spinal cord injury unit. SCI Nurs. Spring 1988;5(2):21.
77. Ooi GC, Ngan H, Peh WC, Mok MY, Ip M. Systemic lupus erythematosus patients with respiratory symptoms: the value of HRCT. Clin Radiol. Oct 1997;52(10):775-81. doi:10.1016/s0009-9260(97)80159-6
78. Hariri LP, Unizony S, Stone J, et al. Acute fibrinous and organizing pneumonia in systemic lupus erythematosus: a case report and review of the literature. Pathol Int. Nov 2010;60(11):755-9. doi:10.1111/j.1440-1827.2010.02586.x
79. Quadrelli SA, Alvarez C, Arce SC, et al. Pulmonary involvement of systemic lupus erythematosus: analysis of 90 necropsies. Lupus. Oct 2009;18(12):1053-60. doi:10.1177/0961203309106601
80. Spira D, Wirths S, Skowronski F, et al. Diffuse alveolar hemorrhage in patients with hematological malignancies: HRCT patterns of pulmonary involvement and disease course. Clin Imaging. Jul-Aug 2013;37(4):680-6. doi:10.1016/j.clinimag.2012.11.005
81. Andrade C, Mendonca T, Farinha F, et al. Alveolar hemorrhage in systemic lupus erythematosus: a cohort review. Lupus. Jan 2016;25(1):75-80. doi:10.1177/0961203315605365
82. Kwok SK, Moon SJ, Ju JH, et al. Diffuse alveolar hemorrhage in systemic lupus erythematosus: risk factors and clinical outcome: results from affiliated hospitals of Catholic University of Korea. Lupus. Jan 2011;20(1):102-7. doi:10.1177/0961203310381511
83. MacDonald SL, Rubens MB, Hansell DM, et al. Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT. Radiology. Dec 2001;221(3):600-5. doi:10.1148/radiol.2213010158
84. Ioachimescu OC, Stoller JK. Diffuse alveolar hemorrhage: diagnosing it and finding the cause. Cleve Clin J Med. Apr 2008;75(4):258, 260, 264-5 passim. doi:10.3949/ccjm.75.4.258
85. Flaherty KR, Travis WD, Colby TV, et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med. Nov 1 2001;164(9):1722-7. doi:10.1164/ajrccm.164.9.2103074
86. Fang X, Luo B, Yi X, et al. Usual interstitial pneumonia coexisted with nonspecific interstitial pneumonia, What's the diagnosis? Diagn Pathol. Dec 3 2012;7:167. doi:10.1186/1746-1596-7-167
87. Perez HD, Kramer N. Pulmonary hypertension in systemic lupus erythematosus: report of four cases and review of the literature. Semin Arthritis Rheum. Aug 1981;11(1):177-81. doi:10.1016/0049-0172(81)90098-6
88. Kim HG, Tashkin DP, Clements PJ, et al. A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients. Clin Exp Rheumatol. Sep-Oct 2010;28(5 Suppl 62):S26-35.
89. Sant SM, Doran M, Fenelon HM, Breatnach ES. Pleuropulmonary abnormalities in patients with systemic lupus erythematosus: assessment with high resolution computed tomography, chest radiography and pulmonary function tests. Clin Exp Rheumatol. Sep-Oct 1997;15(5):507-13.
90. Furuta GT, Atkins D, Capocelli KE, de Zoeten EF, Fleischer D, Menard-Katcher C. Antitumor necrosis factor, infliximab, and adalimumab: use with caution in eosinophilic bowel disease. J Pediatr Gastroenterol Nutr. Oct 2013;57(4):e25. doi:10.1097/MPG.0b013e3182a1e13b
91. Hoffmann-Vold AM, Fretheim H, Halse AK, et al. Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort. Am J Respir Crit Care Med. Nov 15 2019;200(10):1258-1266. doi:10.1164/rccm.201903-0486OC
92. Le Gouellec N, Duhamel A, Perez T, et al. Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease. PLoS One. 2017;12(8):e0181692. doi:10.1371/journal.pone.0181692
93. Hax V, Bredemeier M, Didonet Moro AL, et al. Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis. Semin Arthritis Rheum. Oct 2017;47(2):228-234. doi:10.1016/j.semarthrit.2017.03.019
94. de Oliveira Martins LV, Oliveira SM, Silvatti J, de Amorim FG, Agapito Tito CV, Kayser C. Mortality in Systemic Sclerosis-Associated Interstitial Lung Disease in Brazil: A Real-Life, Long-Term Follow-up Observational Study. J Clin Rheumatol. Mar 1 2022;28(2):e532-e538. doi:10.1097/RHU.0000000000001792
95. Rivas-Vargas D, Snih SA, Rodriguez MA. Characterization of Venezuelan Patients With Systemic Sclerosis: A Study in a Tertiary Hospital in Caracas. Reumatol Clin (Engl Ed). Oct 7 2020;doi:10.1016/j.reuma.2020.06.006
96. Els Vandecasteele KM, Kristof Thevissen, Michel De Pauww, Ellen Deschepper, sasaki Decuman, Yves Piette, FILIP De Keyser, Guy Brusselle, Vanessa Smith. Prevalence and incidence of pulmonary arterial hypertension: 10-year follow-up of an unselected systemic sclerosis cohort. original article. Journal of Scleroderma and Related Disorders. November 28, 2017 2017;2(3):196-202.
97. Mulkoju R, Saka VK, Rajaram M, et al. Pulmonary Manifestations in Systemic Sclerosis: Hospital-Based Descriptive Study. Cureus. Jun 16 2020;12(6):e8649. doi:10.7759/cureus.8649
98. Noviani M, Saffari SE, Tan JL, et al. Mortality and hospitalization outcomes of interstitial lung disease and pulmonary hypertension in the Singapore systemic sclerosis cohort. Semin Arthritis Rheum. Jun 2020;50(3):473-479. doi:10.1016/j.semarthrit.2019.11.005
99. Sanchez-Cano D, Ortego-Centeno N, Callejas JL, et al. Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group. Rheumatol Int. Mar 2018;38(3):363-374. doi:10.1007/s00296-017-3916-x
100. Fujita J, Yoshinouchi T, Ohtsuki Y, et al. Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis. Ann Rheum Dis. Mar 2001;60(3):281-3. doi:10.1136/ard.60.3.281
101. Okamoto M, Fujimoto K, Sadohara J, et al. A retrospective cohort study of outcome in systemic sclerosis-associated interstitial lung disease. Respir Investig. Nov 2016;54(6):445-453. doi:10.1016/j.resinv.2016.05.004
102. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. Jun 1 2008;177(11):1248-54. doi:10.1164/rccm.200706-877OC
103. Bocchino M, Bruzzese D, D'Alto M, et al. Performance of a new quantitative computed tomography index for interstitial lung disease assessment in systemic sclerosis. Sci Rep. Jul 1 2019;9(1):9468. doi:10.1038/s41598-019-45990-7
104. Vanaken L, Landini N, Lenaerts J, et al. Progressive lung fibrosis and mortality can occur in early systemic sclerosis patients without pulmonary abnormalities at baseline assessment. Clin Rheumatol. Nov 2020;39(11):3393-3400. doi:10.1007/s10067-020-05105-4
105. Zuhur F, Zuhur SS, Zuhur C, Musellim B, Ongen G. Survival in progressive systemic sclerosis with pulmonary involvement: a single-center experience in Istanbul, Turkey. Rheumatol Int. Jun 2012;32(6):1655-61. doi:10.1007/s00296-011-1842-x
106. Takei R, Arita M, Kumagai S, et al. Radiographic fibrosis score predicts survival in systemic sclerosis-associated interstitial lung disease. Respirology. Apr 2018;23(4):385-391. doi:10.1111/resp.13175
107. Moore OA, Goh N, Corte T, et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford). Jan 2013;52(1):155-60. doi:10.1093/rheumatology/kes289
108. Forestier A, Le Gouellec N, Behal H, et al. Evolution of high-resolution CT-scan in systemic sclerosis-associated interstitial lung disease: Description and prognosis factors. Semin Arthritis Rheum. Dec 2020;50(6):1406-1413. doi:10.1016/j.semarthrit.2020.02.015
109. Ariani A. Quantitative Computed Tomography in Systemic Sclerosis-Interstitial Lung Disease: Are We Ready to Go beyond Standard Assessment? Ann Am Thorac Soc. Jan 2021;18(1):183-184. doi:10.1513/AnnalsATS.202008-967LE
110. Goldin JG, Lynch DA, Strollo DC, et al. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest. Aug 2008;134(2):358-367. doi:10.1378/chest.07-2444
111. Kimura N, Gu E, Fujihata T, Kato H. [Ratio of 3 major nutrients compounded in complete intravenous hyperalimentation]. Nihon Rinsho. 1979;37(8):2954-9.
112. Chen M, Liu X, Xu Y, et al. Clinicopathological characteristics of lung cancer in patients with systemic sclerosis. Clin Respir J. Dec 2020;14(12):1131-1136. doi:10.1111/crj.13249
113. Murgia N, Gambelunghe A. Occupational COPD-The most under-recognized occupational lung disease? Respirology. Jun 2022;27(6):399-410. doi:10.1111/resp.14272
114. Duncan F. Moore EK, Rami Eltaraboulsi, Virginia D. Steen. Increased Morbidity and Mortality of Scleroderma in African Americans Compared to Non–African Americans. 1154. Arthritis Care & Research. 2019;71(9):1154-1163. doi:doi 10.1002/acr.23861
115. Goh NS, Hoyles RK, Denton CP, et al. Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis. Arthritis Rheumatol. Aug 2017;69(8):1670-1678. doi:10.1002/art.40130
116. Wang Y, Gargani L, Barskova T, Furst DE, Cerinic MM. Usefulness of lung ultrasound B-lines in connective tissue disease-associated interstitial lung disease: a literature review. Arthritis Res Ther. Sep 18 2017;19(1):206. doi:10.1186/s13075-017-1409-7
117. Kim EA, Lee KS, Johkoh T, et al. Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings. Radiographics. Oct 2002;22 Spec No:S151-65. doi:10.1148/radiographics.22.suppl_1.g02oc04s151
118. Xu L, Yang R, Cao Y, Wang M, Yang X. Risk factors of diffuse alveolar hemorrhage in Chinese patients with systemic lupus erythematosus. Sci Rep. Dec 16 2023;13(1):22381. doi:10.1038/s41598-023-49978-2